{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:11:36Z","timestamp":1787008296497,"version":"build-2736575974"},"reference-count":59,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Population Health Management"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:p>\n                    This study investigated the clinical and economic impact of anti-obesity medications (AOMs; orlistat, liraglutide, phentermine\/topiramate extended-release [ER], naltrexone ER\/bupropion ER) among United States Veterans with obesity participating in Motivating Overweight\/Obese Veterans Everywhere! (MOVE!), a government-initiated weight management program. The study population was identified from electronic medical records of the Veterans Health Administration (2010\u20132020). Clinical indices of obesity and health care resource utilization and costs were evaluated at 6, 12, and 24 months after the initial dispensing of an AOM in the AOM+MOVE! cohort (\n                    <jats:italic toggle=\"yes\">N<\/jats:italic>\n                    \u2009=\u20093732, mean age 57 years, 79% male) or on the corresponding date of an inpatient or outpatient encounter in the MOVE! cohort (\n                    <jats:italic toggle=\"yes\">N<\/jats:italic>\n                    \u2009=\u20097883, mean age 58 years, 81% male). At 6 months postindex, the AOM+MOVE! cohort had better cardiometabolic indices (eg, systolic blood pressure, diastolic blood pressure, total cholesterol, low-density lipoprotein cholesterol, hemoglobin A1c) than the MOVE! cohort, with the trends persisting at 12 and 24 months. The AOM+MOVE! cohort was significantly more likely than the MOVE! cohort to have weight decreases of 5%\u201310%, 10%\u201315%, and &gt;15% and lower body mass index at 6, 12, and 24 months. The AOM+MOVE! cohort also had fewer inpatient and emergency department visits than the MOVE! cohort, which was associated with lower mean total medical costs including inpatient costs. These results suggest that combining AOM treatment with the MOVE! program could yield long-term cost savings for the Veterans Affairs network and meaningful clinical improvements for Veterans with obesity.\n                  <\/jats:p>","DOI":"10.1089\/pop.2022.0227","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T12:56:05Z","timestamp":1675428965000},"page":"72-82","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical and Cost Benefits of Anti-Obesity Medication for US Veterans Participating in the MOVE! Weight Management Program"],"prefix":"10.1177","volume":"26","author":[{"given":"W. Timothy","family":"Garvey","sequence":"first","affiliation":[{"name":"UAB Diabetes Research Center, The University of Alabama at Birmingham, Birmingham, Alabama, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mu","family":"Cheng","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhilasha","family":"Ramasamy","sequence":"additional","affiliation":[{"name":"Novo Nordisk, Inc., Plainsboro, New Jersey, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Gabriel","family":"Smolarz","sequence":"additional","affiliation":[{"name":"Novo Nordisk, Inc., Plainsboro, New Jersey, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suna","family":"Park","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neela","family":"Kumar","sequence":"additional","affiliation":[{"name":"Novo Nordisk, Inc., Plainsboro, New Jersey, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Kim","sequence":"additional","affiliation":[{"name":"Novo Nordisk, Inc., Plainsboro, New Jersey, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maral","family":"DerSarkissian","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Los Angeles, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel H.","family":"Bhak","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody","family":"Wu","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, Massachusetts, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Hansen","sequence":"additional","affiliation":[{"name":"Novo Nordisk, Inc., Plainsboro, New Jersey, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinong","family":"Young-Xu","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Program, White River Junction Veterans Affairs Medical Center, White River Junction, Vermont, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,2,14]]},"reference":[{"key":"e_1_3_7_2_2","unstructured":"Centers for Disease Control and Prevention. Adult Obesity Facts. Updated May 17 2022. https:\/\/www.cdc.gov\/obesity\/data\/adult.html#:\u223c:text=The%20obesity%20prevalence%20was%2039.8 adults%20aged%2060%20and%20older Accessed June29 2022."},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1909301"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/JOM.0000000000001693"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.20410"},{"key":"e_1_3_7_6_2","unstructured":"The Management of Adult Overweight and Obesity Work Group. Department of Veterans Affairs\/Department of Defense Clinical Practice Guideline for the Management of Adult Overweight and Obesity. v3.0 July 2020. https:\/\/www.healthquality.va.gov\/guidelines\/CD\/obesity\/VADoDObesityCPGFinal5087242020.pdf Accessed June28 2022."},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.11.004"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.4158\/EP161365.GL"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-016-3962-1"},{"key":"e_1_3_7_10_2","unstructured":"Department of Veterans Affairs. MOVE! Weight Management Program. https:\/\/www.move.va.gov\/MOVE\/QandA.asp Accessed November2 2021."},{"key":"e_1_3_7_11_2","first-page":"A98","article-title":"Design and dissemination of the MOVE! Weight-Management Program for Veterans","volume":"6","author":"Kinsinger LS","year":"2009","unstructured":"Kinsinger LS, , Jones KR, , Kahwati L, et al. Design and dissemination of the MOVE! Weight-Management Program for Veterans. Prev Chronic Dis, 2009; 6:A98.","journal-title":"Prev Chronic Dis"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2016.6212"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13142-011-0077-4"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-017-3992-3"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2018.01.029"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/cmu064"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40608-018-0225-1"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2015.59"},{"key":"e_1_3_7_19_2","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. Prescription Medications to Treat Overweight & Obesity. June 2021. https:\/\/www.niddk.nih.gov\/health-information\/weight-management\/prescription-medications-treat-overweight-obesity Accessed June30 2022."},{"key":"e_1_3_7_20_2","unstructured":"XENICAL (Orlistat) Prescribing Information (August 2017). Montgomery AL: H2-Pharma. https:\/\/xenical.com\/pdf\/PI_Xenical-brand_FINAL.PDF Accessed November2 2021."},{"key":"e_1_3_7_21_2","unstructured":"SAXENDA (Liraglutide) Prescribing Information (June 2022). Plainsboro NJ : Novo Nordisk. https:\/\/www.novo-pi.com\/saxenda.pdf Accessed June30 2022."},{"key":"e_1_3_7_22_2","unstructured":"QSYMIA (Phentermine and Topiramate Extended-Release) Prescribing Information (March 2022). Campbell CA : VIVUS LLC. https:\/\/qsymia.com\/patient\/include\/media\/pdf\/prescribing-information.pdf Accessed June30 2022."},{"key":"e_1_3_7_23_2","unstructured":"CONTRAVE (Naltrexone HCl and Bupropion HCl) Prescribing Information (November 2021). Brentwood TN : Currax Pharmaceuticals LLC. https:\/\/www.contravehcp.com\/wp-content\/uploads\/Contrave_PI.pdf Accessed March4 2021."},{"key":"e_1_3_7_24_2","unstructured":"WEGOVY (semaglutide) Prescribing Information (June 2021). Plainsboro NJ : Novo Nordisk. https:\/\/www.novo-pi.com\/wegovy.pdf Accessed June30 2022."},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-021-01019-6"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-021-00733-5"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13326"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-021-03160-7"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.7777"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.16595"},{"key":"e_1_3_7_31_2","doi-asserted-by":"publisher","DOI":"10.4158\/EP-2019-0081"},{"key":"e_1_3_7_32_2","doi-asserted-by":"publisher","DOI":"10.1159\/000520217"},{"key":"e_1_3_7_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22462"},{"key":"e_1_3_7_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20810"},{"key":"e_1_3_7_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23075"},{"key":"e_1_3_7_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2048"},{"key":"e_1_3_7_37_2","unstructured":"Department of Veterans Affairs. Corporate Data Warehouse (CDW). https:\/\/www.hsrd.research.va.gov\/for_researchers\/vinci\/cdw.cfm Accessed December16 2021."},{"key":"e_1_3_7_38_2","unstructured":"Department of Veterans Affairs. Cost of VA Staff & Labor. https:\/\/www.herc.research.va.gov\/include\/page.asp?id=cost-stf-labor Accessed December16 2021."},{"key":"e_1_3_7_39_2","unstructured":"Food and Drug Administration . FDA Approves New Drug Treatment for Chronic Weight Management First Since . June 4 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-drug-treatment-chronic-weight-management-first-2014 Accessed June30 2022."},{"key":"e_1_3_7_40_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-200208000-00007"},{"key":"e_1_3_7_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028198"},{"key":"e_1_3_7_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22359"},{"key":"e_1_3_7_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22726"},{"key":"e_1_3_7_44_2","doi-asserted-by":"publisher","DOI":"10.1177\/2042018817692296"},{"key":"e_1_3_7_45_2","first-page":"30","article-title":"Higher hemoglobin A1C and atherogenic lipoprotein profiles in children and adolescents with type 2 diabetes mellitus","volume":"15","author":"Pelham JH","year":"2019","unstructured":"Pelham JH, , Hanks L, , Aslibekyan S, , Dowla S, , Ashraf AP. Higher hemoglobin A1C and atherogenic lipoprotein profiles in children and adolescents with type 2 diabetes mellitus. J Clin Transl Endocrinol, 2019; 15:30\u201334.","journal-title":"J Clin Transl Endocrinol"},{"key":"e_1_3_7_46_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-022-00895-w"},{"key":"e_1_3_7_47_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0203484"},{"key":"e_1_3_7_48_2","article-title":"Socioeconomic status and use of obesogenic and anti-obesity medications in the United States: a population-based study","volume":"11","author":"Lyu B","year":"2022","unstructured":"Lyu B, , Chang AR, , Inker LA, , Selvin E, , Grams ME, , Shin J-I. Socioeconomic status and use of obesogenic and anti-obesity medications in the United States: a population-based study. Lancet Reg Health Am, 2022; 11:100249.","journal-title":"Lancet Reg Health Am"},{"key":"e_1_3_7_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2021.07.004"},{"key":"e_1_3_7_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-016-3949-y"},{"key":"e_1_3_7_51_2","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.88c.12003"},{"key":"e_1_3_7_52_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-020-00422-w"},{"key":"e_1_3_7_53_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.9486"},{"key":"e_1_3_7_54_2","doi-asserted-by":"publisher","DOI":"10.1002\/2327-6924.12481"},{"key":"e_1_3_7_55_2","doi-asserted-by":"publisher","DOI":"10.1002\/osp4.361"},{"key":"e_1_3_7_56_2","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2010.94"},{"key":"e_1_3_7_57_2","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2017.287"},{"key":"e_1_3_7_58_2","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1652185"},{"key":"e_1_3_7_59_2","article-title":"Simulating the fiscal impact of anti-obesity medications as an obesity reduction strategy","volume":"58","author":"Kabiri M","year":"2021","unstructured":"Kabiri M, , Sexton Ward A, , Ramasamy A, et al. Simulating the fiscal impact of anti-obesity medications as an obesity reduction strategy. Inquiry, 2021; 58:0046958021990516.","journal-title":"Inquiry"},{"key":"e_1_3_7_60_2","doi-asserted-by":"publisher","DOI":"10.2196\/diabetes.9867"}],"container-title":["Population Health Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/pop.2022.0227","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/pop.2022.0227","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/pop.2022.0227","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T01:25:58Z","timestamp":1777685158000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/pop.2022.0227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1089\/pop.2022.0227"],"URL":"https:\/\/doi.org\/10.1089\/pop.2022.0227","relation":{},"ISSN":["1942-7891","1942-7905"],"issn-type":[{"value":"1942-7891","type":"print"},{"value":"1942-7905","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}